• Title/Summary/Keyword: Evidence-based Medicine

Search Result 1,266, Processing Time 0.028 seconds

Introduction to Evidence-based Medicine (EBM) (Evidence-Based Medicine에 대한 소개)

  • Choe, Jae-Gol
    • The Korean Journal of Nuclear Medicine
    • /
    • v.35 no.4
    • /
    • pp.224-230
    • /
    • 2001
  • EBM is "the conscientious, explicit and judicious use of current best evidence in mating decisions about the care of the individual patient. It means integrating individual clinical expertise with the best available external clinical evidence from systematic research." EBM is the integration of clinical expertise, patient values, and the best evidence into the decision making process for patient care. The practice of EBM is usually triggered by patient encounters which generate questions about the effects of therapy, the utility of diagnostic tests, the prognosis of diseases, or the etiology of disorders. The best evidence is usually found in clinically relevant research that has been conducted using sound methodology. Evidence-based medicine requires new skills of the clinician, including efficient literature-searching, and the application of formal rules of evidence in evaluating the clinical literature. Evidence-based medicine converts the abstract exercise of reading and appraising the literature into the pragmatic process of using the literature to benefit individual patients while simultaneously expanding the clinician's knowledge base. This review will briefly discuss about concepts of evidence medicine and method of critical appraisal of literatures.

  • PDF

Using evidence-based medicine in terms of practical insurance medicine (보험의학 실무 영역에서 근거중심의학적 접근 방법)

  • Lee, Sinhyung
    • The Journal of the Korean life insurance medical association
    • /
    • v.32 no.1
    • /
    • pp.8-14
    • /
    • 2013
  • Evidence-based medicine(EBM) or evidence-based health care has been used in clinical medicine. Recently, it also has been applied to areas of social medicine such as independent medical examination. Insurance medicine is one of social medicine, as for it's role is maintenance of sound insurance system or for insured of life insurance. Practical application of EBM to the insurance medicine are; confirming question, finding evidence, and evaluation that selected evidence is best or not in terms of practical aspect.

  • PDF

Anti-inflammatory Effects of Sam-chul-kun-bi-tang

  • Lee, Jin-Ah;Ha, Hye-Kyung;Jung, Da-Young;Lee, Ho-Young;Lee, Nam-Hun;Lee, Jun-Kyoung;Huang, Dae-Sun;Shin, Hyeun-Kyoo
    • The Journal of Korean Medicine
    • /
    • v.31 no.3
    • /
    • pp.47-54
    • /
    • 2010
  • Objective: To derive information on the efficacy of Sam-chul-kun-bi-tang (SKT), by evaluating its anti-inflammatory effect. SKT is a widely-used herbal formula in traditional Korean medicine. In man y studies, plant-derived anti-inflammatory efficacies have been investigated for their potential inhibitory effects on lipopolysaccharide (LPS)-stimulated macrophages. This study was performed to examine the anti-inflammatory effects of SKT extract on LPS-stimulated RAW 264.7 cells. Methods: The production of nitric oxide (NO), prostaglandin $(PG)E_2$, tumor necrosis factor (TNF)-$\alpha$ and interleukin (IL)-6 were examined in a macrophage cell line, RAW 264.7 cells, in the presence of SKT. RAW 264.7 cells were incubated with LPS 1 ${\mu}g/mL$ and SKT for 18 hrs. The anti-inflammatory activity of SKT was investigated by carrageenan-induced paw edema in rats. The paw volume was measured at 2 and 4 hrs following carrageenan-induced paw edema in rats. Results: SKT showed inhibitory effect on $PGE_2$, TNF-$\alpha$ and IL-6 in LPS-stimulated RAW 264.7 cells. But SKT was not inhibitory effect on NO by LPS-stimulated RAW 264.7 cells. Administration of SKT (1 g/kg) also showed a reduction in carrageenan-induced paw edema on rats. Conclusion: These results suggest that SKT has anti-inflammatory activities in both in vitro and in vivo models.

Moving towards Evidence-Based Clinical Practice Guidelines

  • Jung, Jae Hung;Franco, Juan VA;Dahm, Philipp
    • Urogenital Tract Infection
    • /
    • v.13 no.3
    • /
    • pp.45-50
    • /
    • 2018
  • The Institute of Medicine in its report "Clinical Practice Guidelines we can trust" defined standards for clinical practice guidelines. However, many guidelines continue to rely on expert opinion and lack a formal framework for moving from evidence to recommendations. These guidelines may or may not be labeled as "consensus statements" and do not meet contemporary standards for guideline documents we would refer to as "evidence-based". Therefore, the Grading of Recommendations Assessment, Development and Evaluation working group developed a novel, rigorous and transparent approach to grading certainty (quality) of evidence. In addition, it created a system for "moving from evidence to decisions", for example for the development of evidence-based guidelines. In this article, we aim to introduce this approach to appraising the certainty of relevant evidence and estimate the benefits and detriments of health care interventions within the larger context of evidence-based medicine.

Evidence-based approach for herbal medicine-safety classification : Human equivalent dose-based the margin of safety (한약의 안전성 등급화를 위한 evidence-based approach : Human equivalent dose-based the margin of safety)

  • Park, Yeong-Chul;Lee, Sundong
    • Journal of Society of Preventive Korean Medicine
    • /
    • v.17 no.3
    • /
    • pp.19-30
    • /
    • 2013
  • This study was aimed to develop a new formula for herbal medicine-safety classification in terms of evidence-based medicine. Recently, human equivalent dose(HED)-based therapeutic index was developed for herbal medicine-safety classification by transforming $LD_{50}$ to HED. However, the use of the $ED_{50}$ and $LD_{50}$ to derive the therapeutic index may be misleading as to safety, depending on the slope of the dose-response curves for therapeutic and lethal effects. To overcome this deficiency, HED-based MOS(Margin of Safety)was developed and suggested in this study. The HED-based MOS developed by using $LD_1$, changing to ALD(approximate lethal dose), and $ED_{99}$. The HED-based MOS seems to be more useful and safer than HED-based therapeutic index since its values for several herbal medicines are basically two times less than the values from HED-based therapeutic index. Thus, HED-based MOS can be a good example of Evidence-based approach for herbal medicine-safety classification.

Introduction of evidence-based practical medicine through safety classification for herbal medicine(1) (한약의 안전성 등급화를 통한 근거중심실용의학적 연구(1) - Aristolochic acid 함유 한약재를 중심으로 -)

  • Park, Yeong-Chul;Lee, Sundong
    • The Journal of Korean Medicine
    • /
    • v.35 no.1
    • /
    • pp.114-123
    • /
    • 2014
  • Objectives: Evidence-based medicine(EBM) advocates the use of up-to-date "best" scientific evidence from health care research as the basis for making medical decisions. EBM also has been applied to traditional Korean medicine(TKM), especially in the field of safety. Recently, the standard prescription for TKM by Korea Institute of Oriental Medicine was published based on toxic index from various toxicity tests. However, there are some limitations when the results from the study based on EBM are applied in clinics. To overcome these imitations, the term "evidence-based practical medicine" was developed and defined as clinically applicable results from the study based on EBM. And safety classification for TKM was suggested as an example of evidence-based practical medicine. Methods: For safety classification for TKM, the data for $LD_{50}$(50% lethal dose), which was transformed to theoretical $LD_1$(1% lethal dose), was analyzed as one of tools for EMB study and divided by maximum dose used in clinics. Results and Conclusions: As a result, human equivalent dose(HED)-based MOS(margin of safety) for korean traditional medicine was calculated and used for safety classification with 5 categories. These categories would be helpful for oriental medicine clinicians to decide the increase and decrease of dosage according to various factors such as patient's sensitivity, potential toxicity of herbal medicines, clinician's experience for better cure. Thus, this safety classification provides some evidences enough that evidence-based practical medicine should be not the same with EBM and defined differently from EBM.

A critique: The good and bad of a review

  • McMullen, Debbie;McClean, Rhett;Pak, Sok Cheon
    • CELLMED
    • /
    • v.5 no.3
    • /
    • pp.16.1-16.3
    • /
    • 2015
  • Evidence based medicine involves using both the individual clinician's expertise and the current best available external clinical evidence from systematic research in deciding on the appropriate care for individual patients. The current approach to evidence based practice in healthcare adds a third component which is patient values. Evidence based practice is thus a triad, in which the practitioner's expertise, research evidence and the patient's values are all given consideration. The balance to be struck between them depends on the individual case. The literature indicates that complementary medicine practitioners are moving away from traditional knowledge and towards the use of evidence based practice in their clinical discussions. In the context of the daily practice of complementary medicine practitioners and their continuing development of their knowledge base of evidence based practice, this short review discusses the good and bad of a review journal article.

The Need for Evidence-Based Treatment and Standardization in Korean Medicine - Focusing on Consumer Opinions from the Ministry of Health and Welfare's Survey on Usage of Korean Medicine (2008, 2011, and 2014) - (한의학에서 근거중심진료와 표준화의 필요성 - 2008, 2011, 2014년 한방의료이용실태조사(보건복지부)중 소비자의견을 중심으로 -)

  • Sung, Angela Dong Min;Heo, Seung;Oh, Hyun Ho;Lee, Jung Jun;Park, Sung Joon;Lee, Sundong
    • Journal of Society of Preventive Korean Medicine
    • /
    • v.20 no.3
    • /
    • pp.31-43
    • /
    • 2016
  • Objectives : It focuses on what the consumers expected Korean medicine to improve on, and analyzes patients' impressions. Methods : This research is based on the Ministry of Health and Welfare's Survey on Usage of Korean Medicine (2008, 2011, and 2014) and was new analysis for our research objective. Results : The general consensus among the consumers was uncertainty of effectiveness, expensive costs, side effects, need for expertise, lack of scientific evidence, expansion of diseases treated, and improvement of equipment. Consumers distrusted Korean medicine due to its uncertainty of its effectiveness, expensive costs, side effects, and lack of scientific evidence for its effectiveness, and avoided using Korean medicine. Conclusions : These results seem to be a combination of the Korean medicinal doctors treating patients not based on evidence but on their individual experiences, lack of health insurance for Korean medicine resulting in expensive costs, lack of research on toxicity and safety of Korean medicine, and lack of scientific and clinical studies for evidence-based research. To solve these problems, the Korean medicine community needs to standardize treatments based on evidence, and look to Chinese medicine for possible solutions.

Overview of Methodological Quality of Systematic Reviews about Gastric Cancer Risk and Protective Factors

  • Li, Lun;Ying, Xiang-Ji;Sun, Tian-Tian;Yi, Kang;Tian, Hong-Liang;Sun, Rao;Tian, Jin-Hui;Yang, Ke-Hu
    • Asian Pacific Journal of Cancer Prevention
    • /
    • v.13 no.5
    • /
    • pp.2069-2079
    • /
    • 2012
  • Background and Objective: A comprehensive overall review of gastric cancer (GC) risk and protective factors is a high priority, so we conducted the present study. Methods: Systematic searches in common medical electronic databases along with reference tracking were conducted to include all kinds of systematic reviews (SRs) about GC risk and protective factors. Two authors independently selected studies, extracted data, and evaluated the methodological qualities and the quality of evidence using R-AMSTAR and GRADE approaches. Results: Beta-carotene below 20 mg/day, fruit, vegetables, non-fermented soy-foods, whole-grain, and dairy product were GC protective factors, while beta-carotene 20 mg/day or above, pickled vegetables, fermented soy-foods, processed meat 30g/d or above, or salty foods, exposure to alcohol or smoking, occupational exposure to Pb, overweight and obesity, helicobacter pylori infection were GC risk factors. So we suggested screening and treating H. pylori infection, limiting the amount of food containing risk factors (processed meat consumption, beta-carotene, pickled vegetables, fermented soy-foods, salty foods, alcohol), stopping smoking, avoiding excessive weight gain, avoidance of Pb, and increasing the quantity of food containing protective components (fresh fruit and vegetables, non-fermented soy-foods, whole-grain, dairy products). Conclusions: The conclusions and recommendations of our study were limited by including SRs with poor methodological bases and low quality of evidence, so that more research applying checklists about assessing the methodological qualities and reporting are needed for the future.

Development of an Evidence-Based Clinical Practice Guideline of Korean Medicine for Stroke: A Study Protocol

  • Han, Chang-ho;Kim, Mikyung
    • The Journal of Korean Medicine
    • /
    • v.39 no.4
    • /
    • pp.30-39
    • /
    • 2018
  • Introduction: The aim of this study protocol is to share and disclose the methodology used to develop an evidence-based clinical practice guideline (CPG) of therapeutic interventions used in Korean medicine for patients with stroke. Methods: The CPG development process will consist of two phases. In phase I, a development committee will be established, and they will decide the key questions to be answered. A systematic review and meta-analysis will be performed to answer these key questions by searching relevant randomized controlled trials and systematic reviews. Draft recommendations will be developed according to the evidence level and recommendation grades primarily determined using the GRADE methodology. Panels comprised of external experts will be formed, and surveys and a face-to-face meeting will be conducted to reach a consensus on the recommendations. A preliminary guideline will be created after final review by the development committee. In phase II, we will conduct clinical trials and economic analysis to supplement the lack of evidence found in the phase I. Conclusion: The CPG is expected to help doctors practicing Korean medicine in clinics or hospitals with making decisions based on the most reliable evidence, ultimately leading to the provision of optimal care for patients with stroke.